ReviewVirulence2021
Pathogenicity and virulence of
Review in Virulence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Pathogenicity and vaccine protection of circulating pertactin- and filamentous hemagglutinin-deficientEmerging microbes & infections · 2026Article
- ZoonoticEmerging microbes & infections · 2026Article
- Immunological insights into why pertussis continues to be endemic.Human vaccines & immunotherapeutics · 2026Review
- Article
- Covalently Linked Peptides and Membrane Potential Enable CyaA Segment Translocation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Screening pertactin-specific antibodies and evaluating competitive epitope recognition by native mass spectrometry.Chemical science · 2026Article
- Review
- Sudden pertussis outbreaks in Guro-gu, Seoul: epidemiological characteristics and contributing factors in 2024.Child health nursing research · 2026Article
- An Enzymatic Recombinase Amplification Coupled Lateral Flow Assay for Rapid, Visual, and Cost-Effective Detection of Bordetella pertussis.Current microbiology · 2026Article
- Programmable trivalent nanocage vaccine confers durable cross-species protection against Bordetella bronchiseptica infection.Journal of nanobiotechnology · 2026Article
- Antibody waning and Bordetella pertussis resurgence after the COVID-19 pandemic in the Netherlands.Nature communications · 2026Article
- Exploring the IS-capades ofMicrobial genomics · 2026Article
- CrpH ofFrontiers in microbiology · 2026Article
- Clinical characteristics of pertussis in infants and risk factors for respiratory support.Annals of medicine · 2025Article
- An IS element-driven antisense RNA attenuates the expression of serotype 2 fimbriae and the cytotoxicity ofEmerging microbes & infections · 2025Article
- Pertussis-A Re-Emerging Threat Despite Immunization: An Analysis of Vaccine Effectiveness and Antibiotic Resistance.International journal of molecular sciences · 2025Review
- Molecular epidemiology and increasing macrolide resistance of Bordetella pertussis isolates in Guangzhou, China.BMC infectious diseases · 2025Article
- Bordetellae colonization oligosaccharide (b-Cool), a glycan crucial for nasal colonization.Science advances · 2025Article
- Limited response of primary nasal epithelial cells toMicrobiology spectrum · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The highly contagious whooping cough agent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.